We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · April 26, 2021

Effects of Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes

Diabetes Care

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial
Diabetes Care 2021 Apr 15;[EPub Ahead of Print], YJM Op den Kamp, M de Ligt, B Dautzenberg, E Kornips, R Esterline, MKC Hesselink, J Hoeks, VB Schrauwen-Hinderling, B Havekes, J Oscarsson, E Phielix, P Schrauwen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading